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Abstract
Background: Trigeminal sensitization represents a major mechanism underlying migraine attacks and their recurrence.
Nitroglycerin (NTG) administration provokes spontaneous migraine-like headaches and in rat, an increased sensitivity to
the formalin test. Kynurenic acid (KYNA), an endogenous regulator of glutamate activity and its analogues attenuate
NTG-induced neuronal activation in the nucleus trigeminalis caudalis (NTC). The anti-hyperalgesic effect of KYNA
analogue 1 (KYNA-A1) was investigated on animal models specific for migraine pain.
Aim: Rats made hyperalgesic by NTG administration underwent the plantar or orofacial formalin tests. The effect of
KYNA-A1 was evaluated in terms of nocifensive behavior and of neuronal nitric oxide synthase (nNOS), calcitonin gene-
related peptide (CGRP) and cytokines expression in areas involved in trigeminal nociception.
Results: KYNA-A1 abolished NTG-induced hyperalgesia in both pain models; NTG alone or associated to formalin
injection induced an increased mRNA expression of CGRP, nNOS and cytokines in the trigeminal ganglia and central
areas, which was reduced by KYNA-A1. Additionally, NTG caused a significant increase in nNOS immunoreactivity in the
NTC, which was prevented by KYNA-A1.
Conclusion: Glutamate activity is likely involved in mediating hyperalgesia in an animal model specific for migraine.
Its inhibition by means of a KYNA analogue modulates nNOS, CGRP and cytokines expression at peripheral and
central levels.
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Introduction
Migraine pathophysiology is not fully understood,
although it has become evident over the years that
migraine attacks result from a vicious cycle where
trigeminovascular system activation causes dural
neurogenic inﬂammation in a predisposed ‘terrain’
characterized by the dysfunction of the pain control
system. This dysfunction favors the activation of the
trigeminal nerve on one side, leading, on the other, to
its sensitization as a consequence of the repeated release
of inﬂammatory mediators at the dural level.
Numerous lines of evidence suggest the existence of a
condition of trigeminal sensitization in migraineurs,
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which can be detected as hyperalgesia and allodynia
during and between episodes (1). Among the mediators
of migraine-associated hyperalgesia, nitric oxide (NO)
has been implicated in the periphery as well as at cen-
tral sites. The systemic administration of nitroglycerin
(NTG), an NO donor, provokes spontaneous migraine-
like attacks (2), and the facilitation of pain transmission
at the spinal level only in migraine patients (3), prob-
ably as a consequence of a sensitization phenomenon
(4). Analogously, in the rat, NTG induces a condition
of hyperalgesia detectable as an increase in
the nocifensive response to the plantar and orofacial
formalin tests (5,6). Another neurotransmitter that
has been implicated in the mediation of hyperalgesia,
with mechanisms that may be relevant for migraine, is
glutamate. Glutamate dilates intracranial and extracra-
nial blood vessels through activation of N-methyl-
D-aspartate (NMDA) receptors, leading to NO release
(7). Furthermore, it plays a key role in trigeminal noci-
ception, as suggested by the presence of diﬀerent types
of glutamate receptors in the nucleus trigeminalis cau-
dalis (NTC) (8). The role of glutamate in migraine is
also suggested by clinical evidence showing increased
levels in the platelets and plasma of migraineurs (9).
Kynurenic acid (KYNA) is a product of normal metab-
olism of the amino acid L-tryptophan formed from
L-kynurenine. KYNA, through the antagonism of
NMDA receptors (10), and its analogues may exert
modulatory eﬀects in many neuropathological condi-
tions, including migraine pain.
KYNA crosses the blood–brain barrier (BBB)
very poorly, so that has stimulated the synthesis of
several new KYNA analogues, prodrugs or KYNA
amides able to cross the BBB. In particular, it is also
worth noting that the KYNA analogue 1 (KYNA-A1),
N-(2-N,N-Dimethylaminoethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride, shows a more marked
inhibitory eﬀect than KYNA upon NTG-induced neur-
onal activation of second-order sensory neurons in the
NTC (11). Moreover, KYNA-A1 reduces the number
of cells immunoreactive for neuronal NOS (nNOS),
calcitonin gene-related peptide (CGRP) release and
calmodulin-dependent protein kinase II alpha
(CamKIIa) expression in the same nucleus (12,13).
The aim of this study was to investigate the role of
KYNA-A1 in modulating spinal and trigeminal hyper-
algesia induced by NTG, a well-known animal model of
migraine, through the evaluation of KYNA-A1 modu-
lation of the nocifensive response to plantar and orofa-
cial formalin tests (5). Additionally, in order to gain
new insights on KYNA-A1 eﬀect upon the trigeminal
hyperalgesia mechanisms, our attention was focused
speciﬁcally on changes in nNOS, CGRP and cytokine
expression in speciﬁc cerebral and peripheral areas
involved in sensitization.
Material and methods
Adult male Sprague-Dawley rats (weight 175–200 g)
were used. The IASP’s guidelines for pain research in
animals were followed (14). Rats were housed in plastic
boxes in groups of two with water and food available
ad libitum and kept on a 12:12 hours light-dark cycle.
All procedures were in accordance with the European
Convention for Care and Use of Laboratory Animals
and were approved by the Italian Ministry of Health
(Document number 2, 2012).
Drugs
Nitroglycerin (NTG) (Bioindustria L.I.M. Novi Ligure
(AL), Italy) was prepared from a stock solution of
5.0mg/1.5mL dissolved in 27% alcohol and 73% pro-
pylene glycol. For the injections, NTG was further
diluted in saline (0.9% NaCl) to reach the ﬁnal concen-
tration of alcohol 6% and propylene glycol (PG) 16%
(used as NTG vehicle). The KYNA-A1 was synthesized
in the laboratory of Dr Ferenc Fu¨lo¨p (Department of
Pharmaceutical Chemistry, Faculty of Pharmacy,
University of Szeged) and was freshly prepared daily
by dilution in saline (90mg/ml) (12).
Experimental design
Rats were assigned to the plantar or orofacial formalin
test. For both types of formalin test we foresaw the
following four treatment groups, each formed by 6–12
animals: 1) Control; 2) KYNA-A1; 3) NTG and 4)
KYNA-A1þNTG.
Vehicle or NTG (10mg/kg) were injected intraperi-
toneally (i.p.) and rats were exposed to plantar or oro-
facial formalin test four hours later (5,6). The latency of
four hours was selected in agreement with our previous
observations, as it corresponds to the timing of max-
imal neuronal activation induced by NTG (5,6).
Group 4 (KYNA-A1þNTG) was formed by two sub-
sets of animals that were randomized to one of the fol-
lowing treatment schedules: a) in order to investigate the
inhibitory eﬀect of KYNA-A1 on NTG-induced hyper-
algesic responses, a dose of 300mg/kg was administered
i.p. 30 minutes before NTG/vehicle administration; b) in
order to evaluate the potential abortive eﬀect of KYNA-
A1 on NTG-induced trigeminal hyperalgesia, in another
experimental group of rats KYNA-A1 (300mg/kg i.p.)
was administered three hours after NTG/vehicle.
Rats were assigned to formalin test type and treat-
ment groups according to a randomization list to
ensure blinding to treatments of the researchers who
performed the behavioral testing. Animals were accli-
matized to the test chamber 30 minutes before testing.
Following nociceptive tests, to decrease pain or distress
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in the animal, each rat was sacriﬁced with a lethal dose
of anesthetic (Zoletil 100, 300mg/Kg, intramuscular).
Plantar formalin test
One animal at a time was placed into a plexiglass obser-
vation chamber (10 20 24 cm) with a mirror (45
angle) positioned to permit unhindered observation of
the animal’s paws. A 100 ml volume of 1% formalin
solution (formaldehyde diluted in 0.9% saline) was
injected subcutaneously into the center of the plantar
surface of the right hind paw with slight restraint (15).
A 26-gauge needle connected to a 1ml syringe was
used, and the solution was delivered as rapidly as pos-
sible while the animal was immobilized.
Pain-related behavior was quantiﬁed for one hour
by counting spontaneous ﬂinches and shakes of the
injected paw: over 60 second periods for the ﬁrst ﬁve
minutes and thereafter following four minute pauses,
for one minute periods up to the hour. Phase I was
deﬁned as the period from one to ﬁve minutes, phase
II was deﬁned as the period from 15 to 60 minutes
inclusive. Flinches/shakes were readily discriminated
and were characterized as rapid and brief withdrawal
movements or ﬂexions of the injected paw.
Orofacial formalin test
The box of observation was a 30 30 30 cm glass
chamber with mirrored sides. A camera, recording
animal behaviors for oﬀ-line analysis, was located at
a distance of 50 cm from the box to provide a clear
view of each rat.
A 50ml volume of 1.5% formalin solution was injected
subcutaneously into the right upper lip. Immediately
after formalin injection, each animal was placed into
the observation box and its behavior recorded for a
45-minute period (16). The pain–related behavior was
quantiﬁed by counting the seconds spent by the animal
in grooming the injected area with the ipsilateral fore- or
hind-paw counted separately for phase I (0–6 minutes
after formalin injection) and phase II (12–45 minutes
after formalin injection) of the test. The observation
time was divided into 15 blocks of three minutes each
for the time course analysis.
CGRP, nNOS, TNF-alpha and IL-6 mRNA
expression following the orofacial formalin test
Rats injected with NTG or vehicle and treated 30 min-
utes before with KYNA-A1 were killed with a lethal
dose of anaesthetic 60 minutes after orofacial formalin
injection. Their medulla-pons (bregma, 13.30 to
14.60mm), cervical spinal cord (C1-C2, CSC) and
the trigeminal ganglia (TGs) were immediately chopped
into parts and frozen at –80C until further processing.
The mRNA expression of all genes was evaluated in the
medulla-pons in toto and in the TGs and the CSC ipsi-
lateral and contralateral to the formalin injection.
CGRP, nNOS, TNF-alpha and IL-6 mRNA expression
was analyzed by a real-time polymerase chain reaction
(RT-PCR, light Cycler 480 Instrument Detection System,
Roche) as previously described (17). Primer sequences,
obtained from the AutoPrime software (http://www.
autoprime.de/AutoPrimeWeb), are reported in Table 1.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as a housekeeping gene and its expression
remained constant in all the experimental groups
considered.
CGRP and nNOS protein expression in the NTC
following the orofacial formalin test
CGRP and nNOS protein expression was evaluated
separately on each side of the NTC 60 minutes after
the orofacial formalin injection. Rats were anaesthe-
tized and perfused transcardially with saline and
270–300ml of ice-cold 4% paraformaldehyde. The
CSC and medulla were removed, post-ﬁxed for 12 h in
the same ﬁxative and subsequently transferred into solu-
tions of sucrose at increasing concentrations (up to 30%)
during the following 72 h. All samples were cut at
50 mm on a freezing sliding microtome. CGRP and
nNOS protein expression was evaluated using
the free-ﬂoating immunohistochemical technique (6).
For CGRP we used an anti-rabbit antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA)
at a dilution of 1:3200. For nNOS we used an anti-
goat antibody (Abcam, Cambridge, UK) at a dilution
of 1:1000. CGRP/nNOS immunoreactivity was visua-
lized with the peroxidase substrate kit DAB
Table 1. Primer sequences.
Gene Forward primer Reverse primer
GAPDH AACCTGCCAAGTATGATGAC GGAGTTGCTGTTGAAGTCA
Calca CAGTCTCAGCTCCAAGTCATC TTCCAAGGTTGACCTCAAAG
nNos CCGGCTACACTTCTCCTCAC CACGAAGCAGGGGACTACAT
TNF-alpha CCTCACACTCAGATCATCTTCTC CGCTTGGTGGTTTGCTAC
IL-6 TTCTCTCCGCAAGAGACTTC GGTCTGTTGTGGGTGGTATC
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(3030-diaminobenzidine tetrahydrochloride) (Vector
Laboratories, Burlingame, CA, USA).
Experimental groups, timing of treatments/tests
and parameters evaluated
Four groups of animals underwent the plantar formalin
test as illustrated in Table 2. An additional set of eight
groups of animals underwent the orofacial formalin test
as illustrated in Table 3 and 4.
Statistical evaluation
An a priori power analysis was conducted to deter-
mine the minimal sample size needed to obtain a stat-
istical power of 0.80 at an alpha level of 0.05. On the
basis of our previous studies evaluating the total
number of ﬂinches/shakes in phase II of the plantar
formalin test, between rats injected with NTG and rats
injected with its vehicle, we calculated a standardized
eﬀect size of 1.62 for this variable (GPower 3.1.9.2),
estimating a sample size of at least six rats for each
experimental group. However, since the orofacial for-
malin test shows an intergroup variability, we have
used a maximum of 12 rats. All data were tested for
normality using the Shapiro-Wilk and KS normality
tests and considered normal. The diﬀerences between
groups or between ipsilateral and contralateral sides
were analyzed by one-way or two-way analysis of vari-
ance (ANOVA) followed by Newman-Keuls Multiple
Comparison Test or Bonferroni post-hoc test. Data
are expressed as meanSEM. For the plantar and
orofacial formalin tests, the nocifensive behavior was
evaluated separately for phase I and for phase II. For
mRNA expression, results were analyzed using the
Ct method to compare expression of genes of inter-
est with that of GAPDH. Optical density (OD) values
were taken to indicate the expression of CGRP in
NTC as suggested by the previous report (18). For
nNOS immunoreactive neurons, we counted those
exhibiting cytoplasmic staining in the NTC using an
AxioSkop 2 microscope (Zeiss).
Table 3. Experimental paradigm used for the orofacial formalin test (KYNA-A1 30 minutes before NTG or NTG vehicle injection).
Group name
Total N¼ 48
(five rats were excluded
from quantification
of nocifensive behaviour) 30’ 0 þ240’ þ241–285’ þ285’–300’
Control (CT) Saline NTG vehicle
Orofacial injection
of formalin
Quantification of
nocifensive behaviour
N¼ 8–12 for group
Expression of Calca,
nNos, TNF-alpha
and IL-6 mRNAs in
trigeminal ganglion, cervical
spinal cord and
medulla-pons;
(N¼ 6 for each
experimental group)
or
Expression of CGRP
and nNOS proteins
in nucleus trigeminalis
caudalis (N¼ 6 for each
experimental group)
KYNA-A1 KYNA-A1 NTG vehicle
NTG Saline NTG
KYNA-A1/NTG KYNA-A1 NTG
Table 2. Experimental paradigm used for the plantar formalin test.
Group name
Total N¼ 28 30’ 0 þ240’ þ240–300’
Control (CT) Saline NTG vehicle
Plantar injection
of formalin
Quantification of
nocifensive behavior
N¼ 6–8 for each experimental group
KYNA-A1 KYNA-A1 NTG vehicle
NTG Saline NTG
KYNA-A1/NTG KYNA-A1 NTG
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Results
Plantar formalin test
NTG administration signiﬁcantly increased nocifensive
behavior in phase II compared to NTG vehicle, in
agreement with our previous ﬁndings (5). No diﬀer-
ences were observed between groups as regards phase
I of the test. In phase II, KYNA-A1 administered 30
minutes before NTG vehicle did not inﬂuence formalin-
induced nocifensive behavior per se, but it prevented
NTG-induced hyperalgesic behavior, as suggested by
the observed signiﬁcant decrease in the total number
of ﬂinches/shakes in phase II of the test. Data are
shown in Figure 1.
Orofacial formalin test
NTG administration signiﬁcantly increased the time
spent in face rubbing during phase II of the orofacial
formalin test compared to the CT group. No diﬀerences
were observed between groups in phase I of the test.
In phase II, KYNA-A1 administered 30 minutes before
or three hours after NTG vehicle did not show any
eﬀect on the face rubbing behavior induced by formalin
injection per se, but it prevented NTG-induced hyper-
algesia, as suggested by the attenuation of face rubbing
behavior. Data are shown in Figure 2.
mRNA expression of nNOS, CGRP
and cytokines during the orofacial
formalin test
Formalin injection per se (CT group) induced an
increase in mRNA expression of all the investigated
genes in all areas under evaluation, when compared
to rats injected with saline into the right upper lip
(data not shown).
Medulla pons
We did not detect any signiﬁcant diﬀerences in this area
between the CT and KYNA-A1 groups. NTG admin-
istration caused a marked and signiﬁcant increase in the
expression of mRNA of all genes compared to the CT
group. KYNA-A1 did not inﬂuence the formalin-
induced increase in mRNA levels of genes in the
areas under investigation, but it prevented the increase
induced by NTG administration in mRNA levels of all
genes. Data are shown in Figure 3.
Cervical spinal cord (CSC) and Trigeminal
Ganglion (TG)
NTG administration induced a marked and signiﬁcant
increase in the expression of mRNA of all genes as
compared to the CT group. KYNA-A1 prevented this
increase. When analyzing diﬀerences between the for-
malin-injected versus the non-injected side, we did not
ﬁnd any signiﬁcant diﬀerence in nNOS gene expression
in any of the experimental groups. At variance with
this, we detected a signiﬁcant diﬀerence between sides
in CGRP and cytokines mRNA expression in both
areas, with more expression on the formalin-injected
side (Figures 4a and 5a).
A signiﬁcant increase in IL-6 mRNA and
TNF-alpha expression was observed in the CSC only
on the formalin-injected side of the NTG group.
KYNA-A1 administration inhibited this increase.
Cytokines mRNA expression increased on both TGs
of NTG-injected rats. KYNA-A1 administration sig-
niﬁcantly inhibited the observed formalin-induced
increase in the NTG group. Data are shown in
Figures 4b and 5b.
Protein expression of CGRP and nNOS in the NTC
during orofacial formalin test
No diﬀerence was found in the OD of CGRP ﬁbers
between both sides of the NTC following formalin
injection in all experimental groups. NTG administra-
tion did not induce any signiﬁcant changes in CGRP
staining in the NTC compared to the CT group.
nNOS-positive cells and ﬁbers were visible on both
sides of NTC in all experimental groups. No signiﬁcant
diﬀerence in nNOS-immunopositive cells between the
two sides was reported one hour after formalin
Table 4. Experimental paradigm used for the orofacial formalin test (KYNA-A1 3 hours after NTG or
NTG vehicle injection).
Group name
Total N¼ 28 0 þ180’ þ240 þ241–285’
Control (CT) NTG vehicle Saline
Orofacial injection
of formalin
Quantification of
nocifensive behavior
N¼ 6–8 for each
experimental group
KYNA-A1 NTG vehicle KYNA-A1
NTG NTG Saline
NTG/KYNA-A1 NTG KYNA-A1
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injection. NTG administration induced a signiﬁcant
increase in nNOS protein expression on both sides of
the NTC compared to the CT group. This increase was
partially but signiﬁcantly attenuated by KYNA-Al pre-
treatment. Data are shown in Figure 6.
Discussion
Several lines of evidence suggest the presence of a state
of central and peripheral sensitization in migraine sub-
jects. Allodynia and hyperalgesia, the clinical correlate
of sensitization, are related to activation of NMDA
receptors in the dorsal horn of the spinal cord (19).
Activation of these receptors, which increase calcium
conductance, leads to protein kinase activation, the
release of serotonin, bradykinin and prostaglandins,
NOS activation and, consequently, NO synthesis.
In this study, we used the model of NTG-induced
hyperalgesia at the spinal and trigeminal level (5,6) to
investigate the eﬀects of KYNA-A1. Additionally, we
investigated the targets and mediators modulated by
the compound in the peripheral and central areas
involved in trigeminal nociception.
Characterization of nitroglycerin induced-
hyperalgesia at the trigeminal level
NTG-induced hyperalgesia in the orofacial formalin
test was associated with an increased nNOS and
CGRP mRNA expression in central areas containing
the NTC. In the NTC, we detected an increase in nNOS
immunoreactivity and a tendency toward a decrease in
the staining of CGRP ﬁbers. These ﬁndings are in
agreement and expand on previous studies (18) to sug-
gest that NTG administration induces a rapid release of
CGRP from ﬁbers originating in the NTC, which, at
four hours, is already recovering as a consequence of
the compensating activation of the Calca gene (12,18).
This is in agreement with other studies that showed an
increase in CGRP release from the TGs neurons during
neurogenic inﬂammation or after NO donor treatment
with activation of Calca gene transcription (20,21).
Also at the peripheral level, in the TGs we observed
an increase in nNOS and CGRP mRNA, but this was
more marked on the formalin-injected side, suggesting
that the phenomenon was related to both types of sti-
muli used in our model, NTG and formalin, but more
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Figure 1. Effects of KYNA-A1 on nitroglycerin-induced hyperalgesia in the plantar formalin test. In panel a, the histograms illus-
trate the total number of flinches and shakes per phase of the test. No significant effect was observed in phase I. In phase II,
Nitroglycerin (NTG) administration significantly increased the total number of flinches/shakes compared to the CT group
(Control group) and to the KYNA-A1 group. Pretreatment with KYNA-A1 counteracted NTG-induced hyperalgesia. Panel b illus-
trates the time course of the nocifensive behavior in the different groups. Data are expressed as mean SEM. Two-way analysis of
variance (ANOVA) was followed by Newman-Keuls Multiple Comparison Test: **p< 0.01 versus the CT group and versus the KYNA-
A1 group; *** p< 0.001 versus the NTG group.
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variance (ANOVA) followed by Newman-Keuls Multiple Comparison Test: **p< 0.01 versus the CT group and KYNA-A1 group;
p< 0.001 and p< 0.01 versus the NTG group.
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to the latter. These ﬁndings show that systemic NTG
can induce transcriptional changes in nNOS and CGRP
expression, important mediators in the initiation and
maintenance of sensitization (22), and this induction
takes place at both peripheral and central areas.
These data are in agreement with previous data that
demonstrated an up-regulation of CGRP and nNOS
immunoreactivity in primary trigeminal aﬀerents of
rats (23), and an increase in NOS-positive second
order neurons (24). Peripheral eﬀects of NTG infusion
were also seen as a time-dependent increase in CGRP
and nNOS expression in the dura mater (25). At vari-
ance, Eberhardt et al. (26) showed that NTG infusion
did not change CGRP mRNA levels in the TGs.
It seems likely that these conﬂicting results are
related to the diﬀerent doses of NTG used by the vari-
ous groups, the highest dose (10mg/Kg, i.p.) probably
being more likely to have transcriptional eﬀects, as
suggested by the activation of CamKIIa in the NTC
of rat (13).
Cytokines are involved in the development and
maintenance of sensitization of peripheral nociceptors
and second order nociceptive neurons. A correlation
between tissue levels of cytokines and hyperalgesia
has been observed in several painful states (27). In
particular, a signiﬁcant increase in pro-inﬂammatory
cytokines levels was found in the TGs and in spinal
trigeminal nuclei after capsaicin injection in the eye-
brow regions (28), thus conﬁrming a role for inﬂamma-
tion in migraine pathogenesis. Here, we report a
signiﬁcant increase of IL-6 and TNF-alpha mRNA
expression following NTG administration in the CSC
ipsilateral to the formalin injection, while cytokines
gene expression signiﬁcantly increased in both TGs,
though more markedly on the formalin injected side.
This suggests a contribution of NTG in the ampliﬁca-
tion of the formalin-induced nociceptive response, via
additional release of cytokines (30). Probably, NTG-
induced nNOS expression (18,22,31) in turn could
induce the expression of pro-inﬂammatory cytokines
(32), thus prompting glial and neuronal responses to
sustained trigeminal system activation (33).
Characterization of the KYNA-A1 effect
upon NTG-induced hyperalgesia in the orofacial
formalin test
KYNA-A1 pretreatment inhibits NTG-induced hyper-
algesia in the hindpaw, but more importantly for
migraine, also in the trigeminal area. The ﬁndings
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obtained suggest that the state of hyperalgesia induced
by NTG, likely related to the increased availability of
NO at the trigeminovascular level or at central sites (i.e.
the NTC) (31), is to some extent mediated by the acti-
vation of glutamate receptors. Previous studies sug-
gested that KYNA amides exert their eﬀect, similarly
to KYNA (34), via an interaction with glutamate activ-
ity, although no direct evidence was reported. However,
one possibility is that KYNA amides can dissociate into
KYNA (35), which is known to block the glycine site of
NMDA receptors (26). Though in previous studies
MK801 has shown an anti-nociceptive eﬀect on phase
II of the plantar formalin test, in this study KYNA-A1
showed a signiﬁcant anti-hyperalgesic eﬀect in the same
phase only in the presence of NTG. Given the known
anti-nociceptive eﬀects of NMDA antagonists, the
absence of the eﬀect of KYNA on formalin-induced
behavior in rats not pre-treated with NTG was some-
what surprising. Although KYNA-A1 has been exten-
sively studied, its exact mechanisms of action have not
yet been fully clariﬁed. KYNA-A1 is considered a pro-
drug that produces KYNA, an intermediate in the tryp-
tophan catabolic pathway that exerts pharmacological
actions as an NMDA receptor antagonist. One possible
explanation is that NTG may modulate the activity of
kynurenine aminotransferase II (KAT II) (36), the
enzyme that converts L-Kinurenine to KYNA, to
induce alterations in central KYNA and thus glutamate
levels. A decrease in KAT II activity has indeed been
associated with increased cerebral glutamate levels and
thus NMDA activation (37). In addition, the increased
NMDA activation could interfere with opioid receptor
function (38). Anatomical studies, ultrastructural ana-
lyses, and electrophysiological data have indeed sug-
gested interactions between opioid receptors and
NMDA receptors. Thus, it is also possible that the
anti-hyperalgesic eﬀects of KYNA-A1 are related to
modulation of the opiod receptor function (39), which
could be altered after NTG administration, probably
via an increased nNOS activity (40).
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A role for NMDA receptors in central sensitization
has been suggested and linked to nNOS activation.
Administration of NMDA agonists to the paw of rats
causes thermal and mechanical hyperalgesia, which is
blocked by nNOS inhibitors (41). Conversely, spinal
cord injury-induced nNOS expression is attenuated
following NMDA antagonist treatment (42). At
the trigeminal level, the eﬀect of KYNA-A1 upon
NTG-induced hyperalgesia is associated with the
modulation of the transcriptional activation of genes
related to the synthesis of CGRP, nNOS and pro-
inﬂammatory cytokines in TGs and in central areas.
KYNA-A1 also prevented the increase in nNOS pro-
teins in the NTC observed following NTG administra-
tion. These observations suggest that the KYNA-A1
eﬀect may take place both at peripheral and central
levels. A role for glutamate in sensory modulation at
peripheral levels has been suggested by Kung et al. (43),
although Eftekhari et al. (44) have demonstrated that,
in rat TG, neurons expressing CGRP do not contain
glutamate as a cotransmitter. It is noteworthy that Fos-
positive neurons in the NTC co-localize especially with
the NMDA receptor and with nNOS, conﬁrming that
NMDA receptor activation in response to trigeminal
pain may mediate neuronal activation involved in noci-
ception. Reciprocal interactions between CGRP and
NO/NOS have been demonstrated in previous studies
(45), and a co-expression of CGRP and nNOS
was found in the majority of NOS positive neurons
in the TG (23). It seems therefore possible that
KYNA-A1 may act primarily via the interaction with
nNOS expression, which in turn inﬂuences sensory
ﬁbers’ activation and the availability of mediators
such as CGRP.
KYNA-A1 administration also proved able to
reduce mRNA expression of cytokines. This eﬀect
likely related to the inhibition of nNOS expression at
central and peripheral levels, and thus to the reduction
in CGRP release. In agreement with this interpretation,
it has been shown that cytokines may be modulated in
trigeminal pain by nNOS under inﬂammatory condi-
tions (46). Inhibition of nNOS induced by spinal cord
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injury was associated with a marked reduction of neu-
trophil inﬁltration, NF-kB activation and cytokine
levels following MK801 pre-treatment (42).
Collateral findings
It is noteworthy that in baseline condition, formalin
injection per se signiﬁcantly increased mRNA expression
of all the investigated genes in all areas under evaluation
compared to orofacial saline injection (data not shown).
Tissue injury causes the release of various inﬂammatory
molecules, from the damaged endothelial and inﬂamma-
tory cells that activate primary sensory neurons to pro-
duce persistent pain. These peripheral changes in turn
induce the release of additional mediators in the spinal
cord, such as NO and cytokines (47). NO may induce
calcium inﬂux – possibly via membrane depolarization
or cGMP-dependent calcium channels – activate mul-
tiple protein kinases and promote CREB activation,
which is implicated in the transcriptional regulation of
several genes. The primary signaling pathway involved
in the initiation and ampliﬁcation of inﬂammatory
responses is the one that leads to activation of nuclear
factor (NF)-kB transcription factors, which represents a
critical regulatory mechanism of nNOS and cytokine
expression. During inﬂammatory responses, NF-kB
cooperates with the mitogen-activated protein kinases
(MAPKs). MAPKs are important for intracellular
signal transduction and contribute to pain sensitization
through distinct molecular and cellular mechanisms (48).
This complex set of mediators likely represents the
framework on which NTG impacts to further amplify
nociceptive responses in our model.
Conclusions
Our study shows that KYNA-A1, a modulator of glu-
tamate activity, counteracts NTG-induced trigeminal
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hyperalgesia at peripheral and central levels. This eﬀect
is likely mediated by a primary action on nNOS expres-
sion and the consequent modulation of CGRP and
cytokine release at peripheral and central sites.
KYNA-A1 therefore qualiﬁes as a potential therapeutic
option in migraine treatment.
Article highlights
. KYNA-A1 pretreatment abolished NTG-induced hyperalgesia in the trigeminal area in an animal model of
migraine.
. NTG-induced hyperalgesia in the trigeminal area was associated with increased transcriptional activity of
CGRP, nNOS and cytokines in the trigeminal ganglia, cervical spinal cord and medulla-pons, which was
blocked by KYNA-A1 injection.
. KYNA-A1 is a potential therapeutic target for migraine treatment.
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